Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">CBC</td><td class="align_center">Two months after starting hydroxyurea</td><td class="align_center">Four months after starting hydroxyurea</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">White cell count (×10<sup>3</sup>/<i>μ</i>L)</td><td class="align_center">7</td><td class="align_center">6</td></tr><tr><td class="align_left">Haemoglobin (g/dL)</td><td class="align_center">12</td><td class="align_center">12</td></tr><tr><td class="align_left">Platelet (thou/cu mm)</td><td class="align_center">326</td><td class="align_center">325</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Complete blood count after hydroxyurea.</div>

Case Reports in Hematology

tab2

Table 2

Table 2: Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges 